Ryan Dornbier
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $55,359 with a category attached, or 90.3%. Boston Scientific accounts for 93.6% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2020 at $50,005 and has fallen 97.9% since, to $1,028 in 2025. Among urology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $507.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$52K
- Coloplast$2K
- Dornier Medtech America, Inc$195
- Olympus America Inc.$163
- Johnson & Johnson$152
- Astellas Pharma US Inc$132
- plus $1K from 26 others
Across 2 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$10K
What the payments were for
- Speaking & faculty fees$150%
- Grants$50,00090%
- Travel & lodging$1,0142%
- Food & beverage$4,1107%
- Education$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $51,813 |
| Coloplast | 15 | $1,719 |
| Dornier Medtech America, Inc | 1 | $195 |
| Olympus America Inc. | 3 | $163 |
| Johnson & Johnson | 3 | $152 |
| Astellas Pharma US Inc | 3 | $132 |
| AbbVie | 6 | $128 |
| Intuitive Surgical | 1 | $92 |
| Endo Pharmaceuticals Inc. | 5 | $85 |
| Urogen Pharma, Inc. | 3 | $79 |
| Verity Pharmaceuticals Inc. | 4 | $78 |
| Axonics, Inc. | 3 | $63 |
| Cook Medical LLC | 4 | $61 |
| AstraZeneca | 2 | $58 |
| KARL Storz Endoscopy-america | 1 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Tolmar, Inc. | 2 | $43 |
| Accord Healthcare, Inc. | 2 | $43 |
| Vertex | 2 | $39 |
| Endo USA, Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Pfizer | 2 | $35 |
| Conmed Corporation | 1 | $33 |
| Immunitybio, Inc. | 1 | $28 |
| Progenics Pharmaceuticals, Inc. | 2 | $27 |
| Calyxo, Inc. | 1 | $25 |
| Procept Biorobotics Corporation | 1 | $24 |
| Merck | 1 | $18 |
| Bayer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| BD | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,000
- TITAN$1,127
- GENERAL BPH$294
- AMS 700$275
- Dornier MedTech$195
- AMS 700 CXR RTE KIT$145
- AdVance XP$141
- iTIND System$117
- LithoVue$116
- Erleada$111
How this compares
$55,359 in reported general payments places this provider in the 95th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 39 | $32,805 |
| MyrbetriqMirabegron | 56 | $28,148 |
| Tamsulosin Hcl | 299 | $3,271 |
| Solifenacin Succinate | 49 | $2,498 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $725 |
| Finasteride | 63 | $576 |
| Cefdinir | 28 | $483 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $123 |
| Tramadol Hcl | 69 | $115 |
| Ciprofloxacin Hcl | 43 | $106 |
| Levofloxacin | 39 | $84 |
| Oxycodone Hcl | 28 | $75 |
| Trospium Chloride | 15 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $44 | $32,80539 claims |
| Astellas Pharma US IncMyrbetriq | $132 | $28,14856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 urology providers in Iowa.
Other urology in Clive
- Mark KellermanClive$14K
- Trevor WildClive$10K
- Stephanie Courson PothovenClive$8K
- McCabe KennyClive$5K
- Brian GallagherClive$4K
- Jacob JippClive$3K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.